Gilead Sciences submitted a regulatory new drug application (NDA) for its investigational, once-daily single tablet regimen of SOF/VEL/VOX (sofosbuvir, velpatasvir, and voxilaprevir) for the treatment of hepatitis C infection with the viral genotypes 1 to 6.

NEW YORK (Reuters Health) - Despite a sustained virologic response for 12 weeks (SVR12) to direct-acting antiviral agents for recurrent hepatitis C virus (HCV) infection following liver transplantation, some patients continue to have occult infection.

A study in tree shrews — a small mammal that also gets infected with the hepatitis B virus (HBV) — gave researchers a deeper understanding of the innate immune response processes triggered by the virus.

Liver specialists, virologists and immunologists from around the world met at the 3rd International Workshop on a Hepatitis B Cure in Toronto last week to share their advances and brainstorm solutions to the challenges they face as they hunt for a cure for the liver infection that affects 240 million worldwide.

Gilead Sciences’ Vemlidy (tenofovir alafenamide) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic hepatitis B virus (HBV) infection with compensated liver disease.

When we have chronic hepatitis B, knowing our family medical history can give us an inside edge to fight this infection.Hepatitis B is an infection that often runs in families. Knowing how our parents, grandparents and aunts/uncles responded to this liver disease can give us insider information about our own genetic prospects with hepatitis B.

The study, by a team from Baylor College of Medicine in Texas, is published in the journal Cancer Cell."Recent studies have shown that more than 80 percent of the population in the United States adopt a lifestyle that leads to chronic disruption in their sleep schedules," notes Loning Fu, senior author of the study and associate professor at Baylor College of Medicine.

For more than 25 years, Timothy Block, Ph.D,, has worked tirelessly to find a cure for hepatitis B, promoting research, writing papers, mentoring students and collaborating with experts around the world to find a cure for the 240 million people living with this deadly liver disease.

Alcoholic hepatitis is a disease caused by drinking alcohol. The disease causes fat to build up in the liver cells, as well as inflammation and even scarring of the liver.

A new prodrug formulation, tenofovir alafenamide, effectively treats chronic hepatitis B virus (HBV) infection with fewer bone and renal adverse effects than tenofovir disoproxil fumarate, according to two noninferiority trials.